Your browser is no longer supported. Please, upgrade your browser.
BGNE BeiGene, Ltd. daily Stock Chart
BGNE [NASD]
BeiGene, Ltd.
Index- P/E- EPS (ttm)-13.85 Insider Own20.61% Shs Outstand75.04M Perf Week2.44%
Market Cap12.82B Forward P/E- EPS next Y-15.44 Insider Trans-1.03% Shs Float75.04M Perf Month1.75%
Income-827.30M PEG- EPS next Q-4.86 Inst Own68.10% Short Float3.77% Perf Quarter-13.04%
Sales430.00M P/S29.80 EPS this Y-460.00% Inst Trans1.58% Short Ratio8.58 Perf Half Y18.80%
Book/sh21.27 P/B8.03 EPS next Y-15.40% ROA-39.20% Target Price208.92 Perf Year29.17%
Cash/sh16.42 P/C10.40 EPS next 5Y24.00% ROE-53.60% 52W Range113.01 - 210.35 Perf YTD3.03%
Dividend- P/FCF- EPS past 5Y- ROI-35.50% 52W High-18.81% Beta1.15
Dividend %- Quick Ratio5.30 Sales past 5Y77.80% Gross Margin85.50% 52W Low51.13% ATR4.49
Employees3000 Current Ratio5.40 Sales Q/Q-7.60% Oper. Margin- RSI (14)62.69 Volatility2.17% 2.78%
OptionableYes Debt/Eq0.20 EPS Q/Q-102.00% Profit Margin- Rel Volume0.78 Prev Close171.09
ShortableYes LT Debt/Eq0.20 EarningsFeb 26 AMC Payout- Avg Volume329.56K Price170.79
Recom1.90 SMA204.33% SMA501.70% SMA20016.53% Volume257,055 Change-0.18%
Feb-18-20Resumed Goldman Buy
Jan-17-20Upgrade CLSA Outperform → Buy
Jan-17-20Resumed Morgan Stanley Overweight $210
Dec-16-19Downgrade Piper Jaffray Overweight → Neutral
Dec-16-19Downgrade Guggenheim Buy → Neutral
Nov-19-19Downgrade UBS Buy → Neutral
Nov-13-19Downgrade CLSA Buy → Outperform
Nov-04-19Reiterated Maxim Group Buy $170 → $210
Jun-04-19Initiated Bernstein Outperform $201
May-10-19Upgrade CLSA Outperform → Buy
Mar-15-19Initiated BofA/Merrill Buy $200
Jan-04-19Downgrade CLSA Buy → Outperform
Nov-21-18Initiated JP Morgan Overweight $174
Sep-25-18Initiated Leerink Partners Outperform
May-17-18Reiterated Maxim Group Buy $200 → $225
May-14-18Initiated Credit Suisse Outperform
Apr-13-18Initiated Piper Jaffray Overweight $200
Apr-10-18Reiterated Maxim Group Buy $160 → $200
Mar-01-18Reiterated Maxim Group Buy $144 → $160
Nov-14-17Downgrade Robert W. Baird Outperform → Neutral $58 → $83
Feb-18-20 10:49AM  Amgen Inc. -- Moody's assigns Baa1 rating to Amgen's new sr. unsecured notes; stable outlook Moody's
Jan-21-20 07:00AM  BeiGene Announces that the Phase 3 Clinical Trial of its Anti-PD-1 Antibody Tislelizumab in Patients with First-Line Squamous Non-Small Cell Lung Cancer Met the Primary Endpoint of Progression-Free Survival at Interim Analysis GlobeNewswire
Jan-13-20 07:00AM  EUSA Pharma and BeiGene Announce Exclusive Development and Commercialization Agreement for SYLVANT® and QARZIBA® in Greater China GlobeNewswire
Jan-08-20 07:30AM  BeiGene to Present at the 38th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Jan-06-20 08:25AM  Leap Therapeutics Surges on License Agreement With BieGene Zacks
Jan-03-20 02:11PM  Cash-strapped biotech signs deal with Chinese drugmaker BeiGene American City Business Journals
08:53AM  Leap Therapeutics and BeiGene Announce Exclusive Option and License Agreement for DKN-01 and Leap Announces $27 Million Equity Financing PR Newswire
Jan-02-20 08:15AM  BeiGene Announces Closing of Amgen Global Strategic Oncology Collaboration and Equity Investment GlobeNewswire
Dec-30-19 05:17PM  BeiGene Gets Approval for Lymphoma Drug Tislelizumab in China Zacks
Dec-28-19 09:30AM  ROSEN, NATIONAL TRIAL LAWYERS, Continues to Investigate Securities Claims Against BeiGene, Ltd. BGNE GlobeNewswire
Dec-27-19 10:30PM  China National Medical Products Administration Approves BeiGenes Tislelizumab for Patients with Classical Hodgkins Lymphoma Who Have Received at Least Two Prior Therapies GlobeNewswire
Dec-22-19 06:00PM  BeiGene Announces Acceptance of a Supplemental New Drug Application in China for REVLIMID® in Relapsed or Refractory Indolent Lymphoma GlobeNewswire
Dec-20-19 09:25AM  Key AbbVie Drug Faces Competition Worries After Head-to-Head Study Barrons.com
Dec-19-19 04:40PM  These Hedge Funds Cashed Out Of BeiGene, Ltd. (BGNE) Too Early Insider Monkey
Dec-16-19 07:00AM  BeiGene Announces Results of Phase 3 ASPEN Trial of Zanubrutinib Compared to Ibrutinib for the Treatment of Patients with Waldenströms Macroglobulinemia GlobeNewswire -6.21%
Dec-13-19 07:00AM  BeiGene Announces Clinical Data on Investigational Anti-PD-1 Antibody Tislelizumab in Combination with Sitravatinib at European Society for Medical Oncology Immuno-Oncology (ESMO I-O) Congress 2019 GlobeNewswire
Dec-08-19 04:45PM  BeiGene Announces Clinical Data on BRUKINSA (Zanubrutinib) at the 61st American Society of Hematology (ASH) Annual Meeting GlobeNewswire
Dec-02-19 06:02PM  SK Biopharmaceuticals IPO Tabbed to Raise $850 Million GuruFocus.com
Nov-29-19 03:30PM  BGNE LOSS NOTICE: ROSEN, A LEADING LAW FIRM, Continues to Investigate Securities Claims Against BeiGene, Ltd. BGNE GlobeNewswire
Nov-26-19 05:54PM  BeiGene Shares Climb Nearly 50% After Amgen Deal GuruFocus.com
07:00AM  BeiGene to Present at the 31st Annual Piper Jaffray Healthcare Conference GlobeNewswire
Nov-23-19 05:00AM  BeiGene Announces Clinical Data on Tislelizumab Presented at European Society for Medical Oncology (ESMO) Asia 2019 Congress GlobeNewswire
Nov-16-19 08:43AM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of BeiGene, Ltd. - BGNE ACCESSWIRE
Nov-15-19 05:34PM  BeiGene prices lymphoma drug at $12,935 for a 30-day supply Reuters
10:09AM  The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval Benzinga
04:30AM  Stocks Blog: AAC Technologies, BeiGene jump; Hang Seng Index rises as traders look for bargains South China Morning Post
02:00AM  US regulator issues first approval for a Chinese cancer treatment Financial Times
Nov-14-19 04:20PM  U.S. FDA Grants BeiGenes BRUKINSA (zanubrutinib) Accelerated Approval to Treat Adult Patients with Mantle Cell Lymphoma Who Received at Least One Prior Therapy GlobeNewswire
04:01PM  UPDATE 2-China's BeiGene gets FDA approval for drug to treat rare form of lymphoma Reuters
03:49PM  BeiGene drug wins U.S. FDA approval for rare form of lymphoma Reuters
Nov-13-19 03:11PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of BeiGene, Ltd. - BGNE GlobeNewswire
Nov-12-19 04:05PM  BeiGene Reports Third Quarter 2019 Financial Results GlobeNewswire
Nov-11-19 06:30PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of BeiGene, Ltd. - BGNE ACCESSWIRE
Nov-10-19 07:00PM  ROSEN, A LEADING GLOBAL LAW FIRM, Continues to Investigate Securities Claims Against BeiGene, Ltd. BGNE GlobeNewswire
Nov-07-19 05:54PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of BeiGene, Ltd. - BGNE GlobeNewswire
Nov-06-19 10:58AM  Bragar Eagel & Squire, P.C. Is Investigating Merit Medical Systems, Baxter International, Under Armour, and BeiGene on Behalf of Stockholders and Encourages Investors to Contact the Firm GlobeNewswire
09:00AM  BeiGene Announces Clinical Data on Zanubrutinib to Be Presented at the 61st American Society of Hematology Annual Meeting GlobeNewswire
Nov-05-19 10:13AM  The Zacks Analyst Blog Highlights: Navient, BeiGene, SPS Commerce and Chipotle Mexican Grill Zacks
08:00AM  Seattle Genetics and BeiGene Announce Global License Agreement for Advanced Preclinical Product Candidate Business Wire
Nov-04-19 11:18AM  AMAG Q3 Loss Wider Than Expected, Revenues Lag Estimates Zacks
07:56AM  4 Stocks to Buy From Sectors With Maximum Job Gains Zacks
Nov-01-19 06:12PM  BEIGENE ALERT: Bragar Eagel & Squire, P.C. is Investigating BeiGene, Ltd. on Behalf of Stockholders and Encourages Investors to Contact the Firm Business Wire +37.02%
03:18PM  Biotech ETFs Strengthen as Amgen Invests in Chinas BeiGene ETF Trends
02:49PM  Repligen (RGEN) Beats on Q3 Earnings, Lifts 2019 Guidance Zacks
02:40PM  Amgen Inc. -- Moody's: Amgen's BeiGene collaboration will expand geographic reach but reduce cash Moody's
07:38AM  The Daily Biotech Pulse: Amgen Takes 20.5% Stake In BeiGene, Paratek's Mixed Clinical Readout, CareDx Slips On Guidance Benzinga
04:53AM  Amgen to Take $2.7 Billion Stake in BeiGene for China Growth Bloomberg
03:01AM  Jobs Report, Exxon, Pinterest, Amgen, U.S. Steel - 5 Things You Must Know Friday TheStreet.com
Oct-31-19 05:28PM  Amgen Is Taking A $2.7 Billion Stake In A Chinese Biotech Here's Why Investor's Business Daily
04:00PM  BeiGene Announces Global Strategic Oncology Collaboration with Amgen GlobeNewswire
03:49PM  [video]Amgen Takes $2.7 Billion Stake in BeiGene to Expand Access to China TheStreet.com
07:54AM  Have Insiders Been Selling BeiGene, Ltd. (NASDAQ:BGNE) Shares? Simply Wall St.
Oct-30-19 10:00AM  BeiGene, Ltd. (BGNE) is a Great Momentum Stock: Should You Buy? Zacks
Oct-29-19 08:02PM  HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds BeiGene, Ltd. (BGNE) Investors of Ongoing Investigation of Possible Securities Fraud: Investors Who Suffered Losses Encouraged to Contact Firm GlobeNewswire
Oct-28-19 03:30PM  ROSEN, A HIGHLY RANKED LAW FIRM, Continues to Investigate Securities Claims Against BeiGene, Ltd. BGNE Business Wire
Oct-23-19 04:50PM  ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
10:30AM  Were Hedge Funds Right About Dumping BeiGene, Ltd. (BGNE)? Insider Monkey
Oct-18-19 03:35PM  SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
Oct-16-19 04:00PM  IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
Oct-15-19 05:13PM  Reata Successfully Completes Neuromuscular Disorder Study Zacks
Oct-08-19 03:54PM  Lifshitz & Miller LLP Announces Investigation of Aflac Inc., BeiGene, Ltd., Meredith Corporation, New Relic, Inc., Ollie's Bargain Outlet Holdings, Inc., SmileDirectClub, Inc., and Sonim Technologies, Inc. PR Newswire
Oct-07-19 08:05PM  BGNE INVESTOR REMINDER: Hagens Berman Reminds BeiGene, Ltd. (BGNE) Investors of Ongoing Investigation of Possible Securities Fraud GlobeNewswire
04:00PM  ROSEN, A LEADING LAW FIRM, Continues to Investigate Securities Claims Against BeiGene, Ltd. BGNE GlobeNewswire
Oct-01-19 07:19PM  Bragar Eagel & Squire, P.C. Is Investigating Tandy Leather Factory, ADTRAN, BeiGene, and Altria Group on Behalf of Stockholders and Encourages Investors to Contact the Firm GlobeNewswire
Sep-30-19 08:04PM  BGNE INVESTOR REMINDER: Hagens Berman Reminds BeiGene, Ltd. (BGNE) Investors of Ongoing Investigation of Possible Securities Fraud GlobeNewswire
11:30AM  BGNE LOSS NOTICE: ROSEN, A TOP RANKED LAW FIRM, Continues to Investigate Securities Claims Against BeiGene, Ltd. BGNE GlobeNewswire
06:00AM  BeiGene Announces Clinical Data on Tislelizumab and Pamiparib Presented at the European Society for Medical Oncology (ESMO) Congress 2019 GlobeNewswire
Sep-26-19 06:05PM  BeiGene Announces Clinical Data on Tislelizumab and Pamiparib to Be Presented at the European Society for Medical Oncology (ESMO) Congress 2019 GlobeNewswire
Sep-25-19 03:16PM  BGNE LOSSES ALERT: Bernstein Liebhard LLP Shareholders of its Investigation of BeiGene Ltd. PR Newswire
12:12PM  Should You Be Pleased About The CEO Pay At BeiGene, Ltd.'s (NASDAQ:BGNE) Simply Wall St.
09:55AM  ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces It Is Investigating Claims Against BeiGene, Ltd. and Encourages Investors With Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
Sep-23-19 08:06PM  BGNE INVESTIGATION REMINDER: Hagens Berman Reminds BeiGene, Ltd. (BGNE) Investors of Ongoing Investigation of Possible Securities Fraud GlobeNewswire
06:56PM  BGNE LOSS NOTICE: ROSEN, A LEADING LAW FIRM, Continues to Investigate Securities Claims Against BeiGene, Ltd. BGNE Business Wire
Sep-22-19 07:00PM  BeiGene Announces Clinical Results on Tislelizumab Presented at the 22nd Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) GlobeNewswire
Sep-19-19 09:25PM  ONGOING SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
04:45PM  ROSEN, A LEADING LAW FIRM, Continues to Investigate Securities Claims Against BeiGene, Ltd. BGNE GlobeNewswire
Sep-18-19 10:50AM  ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
Sep-17-19 08:02PM  BGNE SHAREHOLDER ALERT: Hagens Berman Reminds Investors in BeiGene, Ltd. (BGNE) of Ongoing Investigation of Possible Securities Fraud GlobeNewswire
12:40PM  SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses in Excess of $50,000 to Contact the Firm ACCESSWIRE
Sep-16-19 04:40PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of BeiGene, Ltd. - BGNE ACCESSWIRE
04:00PM  Glancy Prongay & Murray LLP Continues Its Investigation on Behalf of BeiGene, Ltd. Investors Business Wire
03:15PM  ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses in Excess of $50,000 to Contact the Firm ACCESSWIRE
01:54PM  INVESTOR ALERT: Law Offices of Howard G. Smith Continues Its Investigation on Behalf of BeiGene, Ltd. Investors (BGNE) Business Wire
Sep-15-19 03:15PM  BGNE NOTICE, ROSEN, A GLOBALLY RANKED FIRM, Announces Investigation of Securities Claims Against BeiGene, Ltd.; Encourages Investors with Losses over $100K to Inquire - BGNE ACCESSWIRE
Sep-14-19 07:22AM  SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses in Excess of $50,000 to Contact the Firm ACCESSWIRE
Sep-13-19 10:00PM  Bragar Eagel & Squire, P.C. is Investigating BeiGene, Ltd. (NASDAQ: BGNE) on Behalf of BeiGene Stockholders and Encourages BeiGene Investors to Contact the Firm Business Wire
09:20PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of BeiGene, Ltd. - BGNE ACCESSWIRE
05:06PM  ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
03:00PM  IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses in Excess of $50,000 to Contact the Firm ACCESSWIRE
10:30AM  Glancy Prongay & Murray LLP Announces Investigation on Behalf of BeiGene, Ltd. Investors Business Wire
Sep-12-19 09:10PM  SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses in Excess of $50,000 to Contact the Firm ACCESSWIRE
08:03PM  SHAREHOLDER ALERT: Hagens Berman Notifies Investors in BeiGene, Ltd. (BGNE) of Securities Fraud Investigation PR Newswire
06:57PM  INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of BeiGene, Ltd. Investors (BGNE) Business Wire
05:04PM  INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
04:31PM  ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Announces Investigation of Securities Claims Against BeiGene, Ltd.; Encourages Investors with Losses over $100K to Contact the Firm BGNE GlobeNewswire
02:20PM  SHAREHOLDER ALERT: Investigation of BeiGene Announced by Holzer & Holzer, LLC Business Wire
Sep-11-19 07:48PM  INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
05:36PM  EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against BeiGene, Ltd.; Encourages Investors with Losses over $100K to Contact the Firm BGNE Business Wire
04:30PM  BeiGene Announces Clinical Data to Be Presented at the Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) GlobeNewswire
03:19PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of BeiGene, Ltd. - BGNE GlobeNewswire
BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer in the People's Republic of China, the United States, and internationally. Its commercial products include ABRAXANE, a chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancers; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia. The company's clinical stage drug candidates include BGB-3111, a small molecule Bruton's tyrosine kinase (BTK) inhibitor for the treatment of lymphomas; BGB-A317, a humanized monoclonal antibody for solid and hematological cancers; and BGB-290, a small molecule inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers. In addition, its clinical stage drugs include BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway; BGB-A333, a humanized monoclonal antibody for the immune checkpoint receptor ligand PD-L1; BGB-A425, a TIM-3 inhibitor; MGCD-0516, a multi-kinase inhibitor; CC-122, a cereblon modulator; and BGB-3245, an oral small molecule inhibitor of specific BRAF mutations, including B-RAF non-V600 mutations and RAF fusions for various solid tumor indications. The company has collaborations with Celgene Corporation, Merck KGaA, Mirati Therapeutics, Inc., Zymeworks, BioAtla, LLC, and Ambrx, Inc. BeiGene, Ltd. was founded in 2010 and is headquartered in Beijing, the People's Republic of China.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Huang JaneCMO, HematologyJan 21Option Exercise29.491,50044,2351,500Jan 22 06:59 PM
Huang JaneCMO, HematologyJan 21Sale170.691,500256,0420Jan 22 06:59 PM
OYLER JOHNChief Executive OfficerDec 17Sale160.6262,25910,000,1000Dec 19 04:10 PM
Huang JaneCMO, HematologyDec 16Option Exercise29.491,50044,2351,500Dec 18 06:57 PM
Huang JaneCMO, HematologyDec 16Sale165.141,500247,7100Dec 18 06:57 PM
Huang JaneCMO, HematologyNov 18Option Exercise29.491,50044,2351,500Nov 20 07:19 PM
Liang HowardCFO & Chief Strategy OfficerNov 18Option Exercise6.5025,000162,50025,000Nov 20 07:20 PM
Liang HowardCFO & Chief Strategy OfficerNov 18Sale194.3425,0004,858,6160Nov 20 07:20 PM
Huang JaneCMO, HematologyNov 18Sale194.491,500291,7400Nov 20 07:19 PM
Wang XiaodongChair, Scientific Advisory BrdNov 15Sale202.0539579,8100Nov 18 05:24 PM
Wang XiaodongChair, Scientific Advisory BrdNov 15Sale202.051,496302,2670Nov 18 05:24 PM
Wu XiaobinPresident & GM ChinaNov 15Sale202.051,000202,0500Nov 18 05:22 PM
Wang XiaodongChair, Scientific Advisory BrdNov 14Sale193.572,605504,242395Nov 18 05:24 PM
Wang XiaodongChair, Scientific Advisory BrdNov 14Sale193.318,5041,643,8801,496Nov 18 05:24 PM
Chen Timothy Yung-ChengDirectorNov 05Option Exercise41.014,000164,0404,000Nov 06 06:50 PM
Chen Timothy Yung-ChengDirectorNov 05Sale189.153,800718,772200Nov 06 06:50 PM
Chen Timothy Yung-ChengDirectorNov 04Option Exercise41.014,000164,0404,000Nov 06 06:50 PM
Huang JaneCMO, HematologyNov 04Option Exercise29.4932,900970,22132,900Nov 06 06:51 PM
Wang XiaodongChair, Scientific Advisory BrdNov 04Sale190.001,000190,0000Nov 05 04:22 PM
Huang JaneCMO, HematologyNov 04Sale190.4632,9006,266,0070Nov 06 06:51 PM
Chen Timothy Yung-ChengDirectorNov 04Sale190.494,200800,0730Nov 06 06:50 PM
Wang XiaodongChair, Scientific Advisory BrdNov 01Sale170.001,000170,0000Nov 05 04:22 PM
Wu XiaobinPresident & GM ChinaNov 01Sale180.001,000180,0000Nov 05 04:20 PM
Huang JaneCMO, HematologySep 04Sale129.408210,6110Sep 05 08:15 PM
Huang JaneCMO, HematologySep 03Sale144.452,862413,4200Sep 05 08:15 PM
Chen Timothy Yung-ChengDirectorAug 23Option Exercise31.597,900249,5617,900Aug 27 04:04 PM
Chen Timothy Yung-ChengDirectorAug 23Sale144.968,6141,248,6800Aug 27 04:04 PM
Huang JaneCMO, HematologyAug 12Option Exercise45.312,500113,2752,500Aug 13 04:47 PM
Huang JaneCMO, HematologyAug 12Sale134.742,500336,8550Aug 13 04:47 PM
Huang JaneCMO, HematologyJul 29Option Exercise37.3010,130377,83410,130Jul 31 04:04 PM
Huang JaneCMO, HematologyJul 29Sale134.5410,1301,362,8960Jul 31 04:04 PM
OYLER JOHNChief Executive OfficerJul 08Sale126.873,106394,0550Jul 09 07:23 PM
Wang XiaodongChair, Scientific Advisory BrdJul 01Sale126.464,847612,9370Jul 01 08:27 PM
Huang JaneCMO, HematologyJun 27Sale124.5243053,5420Jul 01 08:30 PM
Liang HowardCFO & Chief Strategy OfficerJun 27Sale9.475,87655,653122,317Jul 01 08:28 PM
Liang HowardCFO & Chief Strategy OfficerMay 21Option Exercise6.5023,200150,80023,200May 22 07:03 PM
Huang JaneCMO, HematologyMay 21Option Exercise45.312,20099,6822,200May 22 07:04 PM
Huang JaneCMO, HematologyMay 21Sale130.062,200286,1320May 22 07:04 PM
Liang HowardCFO & Chief Strategy OfficerMay 21Sale130.2123,2003,020,8600May 22 07:03 PM
Huang JaneCMO, HematologyMay 20Option Exercise45.3130013,593300May 22 07:04 PM
Huang JaneCMO, HematologyMay 20Sale130.1230039,0360May 22 07:04 PM
Glazer Donald W.DirectorMay 13Sale125.1115,0271,880,0280May 15 03:59 PM
Liang HowardCFO & Chief Strategy OfficerMay 06Option Exercise6.501,80011,7001,800May 08 05:53 PM
Liang HowardCFO & Chief Strategy OfficerMay 06Sale130.011,800234,0140May 08 05:53 PM
Wu XiaobinPresident & GM ChinaMay 01Sale124.525,955741,54617,365May 02 04:08 PM
OYLER JOHNChief Executive OfficerMay 01Sale125.182,824353,5050May 02 04:07 PM
Huang JaneCMO, HematologyApr 08Option Exercise29.4914,130416,69414,130Apr 10 06:41 PM
Huang JaneCMO, HematologyApr 08Sale142.7714,1302,017,3150Apr 10 06:41 PM
Glazer Donald W.DirectorMar 14Sale136.1014,9732,037,8250Mar 18 06:30 PM
Huang JaneCMO, HematologyMar 11Option Exercise29.492,56575,6422,565Mar 11 07:38 PM
Huang JaneCMO, HematologyMar 11Sale130.002,565333,4500Mar 11 07:38 PM
Huang JaneCMO, HematologyMar 07Sale140.50719,9760Mar 11 07:38 PM
OYLER JOHNChief Executive OfficerMar 06Sale150.0010015,000100Mar 06 06:32 PM
OYLER JOHNChief Executive OfficerMar 05Sale151.766,230945,4540Mar 06 06:32 PM
OYLER JOHNChief Executive OfficerMar 05Sale152.254,791729,4330Mar 06 06:32 PM
OYLER JOHNChief Executive OfficerMar 04Sale151.349,7901,481,6250Mar 06 06:32 PM
OYLER JOHNChief Executive OfficerMar 04Sale152.014,588697,4260Mar 06 06:32 PM